$GMM

Global Mofy AI Limited's Mofy VFX Supports Visual Effects for iQIYI's Crime Drama Series The Devil Between Us

Global Mofy AI Limited's visual effects brand, Mofy VFX, provided VFX production services for iQIYI's crime drama series "The Devil Between Us," which premiered on February 23, 2026. The series achieved significant popularity, with over 1.59 million pre-release reservations and a high in-platform popularity score, underscoring Mofy VFX's capability in delivering high-quality visual effects for demanding productions. This success highlights the company's expertise in digital content production and strengthens its reputation in the industry.

Original reporting
Published Feb 26, 2026, 5:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 26, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Global Mofy AI Limited's Mofy VFX Supports Visual Effects for iQIYI's Crime Drama Series The Devil Between Us — source image
Decision brief

The 30-second read

$GMMBullishMed
01

Why it matters

The successful collaboration with iQIYI enhances GMM's industry credibility and could lead to increased contracts and revenue.

02

Market read

The news is relevant primarily to investors and stakeholders in the digital content and visual effects industry, with regional focus on Asia.

03

What to watch

Potential delays in project delivery, changes in industry regulation, or competitive pressures could mitigate any positive effects.

Timing: Immediate to short-term (next few trading sessions)

Background

Global Mofy AI Limited's Mofy VFX has established a reputation for delivering high-quality visual effects, supporting major content productions in Asia.

Company-level read

Ticker impact

$GMMBullishMedium confidence
Context

High relevance due to positive sentiment and industry involvement in digital content and visual effects.

Expected impact

Moderate upward movement expected in the short to medium term.

Evidence & confidence

The news highlights successful project execution and industry recognition, which may boost investor confidence. However, the direct financial impact on GMM is not specified, and broader market factors could influence stock movement.

Market effects

Potential positive influence on the digital content and visual effects industry sector.

Likely limited to regions where GMM and iQIYI operate, primarily Asia.

Low; the news is industry-specific and regional.

Counterpoint

The positive sentiment may be overstated; the impact on GMM's stock could be limited if broader market conditions deteriorate.

Key entities

  • Global Mofy AI Limited

    A company specializing in AI-driven visual effects and digital content production.

  • iQIYI

    A major online entertainment service provider in China.

  • The Devil Between Us

    A crime drama series that premiered on February 23, 2026, featuring high-quality visual effects.

Related articles

$GMMMedAI 8/10

Global Mofy Reports 49.4% YoY Revenue Increase for the Six Months Ended March 31, 2026, Driven by Virtual Tech Growth and New AI Digital Asset Business

Global Mofy AI Limited (Nasdaq: GMM) reported six-month results ended March 31, 2026. Revenue rose 49.4% to $39.9 million from $26.7 million. R&D increased to $14.4 million. GAAP net loss was $50.7 million, while non-GAAP net income was $1.1 million, with higher costs tied to virtual production and a new digital asset sales business.

$GMMMedAI 8/10

D. Boral Capital Acted as Exclusive Placement Agent to Global Mofy AI Limited in Connection with its ~$8,000,000 Registered Direct Offering

Global Mofy AI Limited (Nasdaq:GMM) closed a registered direct offering on May 26, 2026, selling 8,247,420 Class A ordinary shares plus Series A and Series B warrants to buy up to 8,247,420 shares each. The offering price was $0.97 per share, raising about $8.0 million gross. D. Boral Capital was exclusive placement agent; net proceeds will fund general corporate purposes.

$GMMMed

Global Mofy Enters into Cooperation with Amazon Web Services (AWS) and Advances AIGC Computing Infrastructure Deployment

Global Mofy AI Limited (Nasdaq: GMM) said it entered into cooperation with Amazon Web Services to upgrade its digital asset library, deploy cloud infrastructure, and provide related technical support, according to the company. It also announced parallel arrangements to advance its self-developed AIGC intelligent content platform and agent products, which may affect how its services are hosted and scaled.

$GDMedAI 9/10

General Dynamics wins $249m in US military contracts

General Dynamics (GD) won two U.S. military contracts totaling $248.9M. One is a $149.6M contract for USS Pinckney modernization, with potential value up to $149.9M. The other is a $99.3M task order for MUOS Ground Infrastructure Segment upgrades. Both contracts are sole-source and involve work through 2028, funded by fiscal 2026 budgets.

$LMTHighAI 9/10

Lockheed Martin wins $150 million in defense contracts

Lockheed Martin Corp received three contract modifications worth over $150 million from the U.S. Department of Defense. The largest, $90.2 million, is for the TRIDENT II Life Extension 2 program, with work spread across multiple locations. The other contracts, $40.1 million and $20.3 million, are for the MK 41 Vertical Launching System and HH-60W repairs, respectively. Completion dates range from 2027 to 2030.

$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.